Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
8 participants
INTERVENTIONAL
2023-08-03
2025-03-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Opioid Drug Interaction Study
NCT06757140
Effects of Buprenorphine and Naloxone in Opiate Addicts - 4
NCT00000355
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
NCT00134914
Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers
NCT02165930
Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids
NCT00218101
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Double-blind marijuana/placebo administration
Participants will receive double-blind administration of vaporized marijuana/placebo
Marijuana
Double-blind administration of marijuana
Opioid
Double-blind administration of an opioid agonist
Double-blind opioid/placebo administration
Participants will receive double-blind administration of intranasal opioid agonist/placebo
Marijuana
Double-blind administration of marijuana
Opioid
Double-blind administration of an opioid agonist
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Marijuana
Double-blind administration of marijuana
Opioid
Double-blind administration of an opioid agonist
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Experience with marijuana and opioids
* General good health
* Willing to live at the University of Kentucky Hospital (research unit) for approx. 6.5 weeks (meals are provided,
Exclusion Criteria
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Shanna Babalonis, PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shanna Babalonis, PhD
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shanna Babalonis, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Kentucky
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kentucky
Lexington, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
45017-20221
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.